Saturday 17 October 2026
Export IDYA’s income statement to Excel — free account
IDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024. In the quarter to June 2026, revenue grew 125.8%, EPS fell 38.6% and free cash flow fell 41.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
32.85
1.00
−2.95%
Follow IDYA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 2 | 3 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
13.26 | 89.76 | 86.63 | 14.14 | 29.83 | 0.00 | — | — | — |
Altman Z-Score |
20.70 | 18.35 | 43.04 | 11.53 | 5.90 | 2.16 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.32 | — | — | — |
Altman Z″-Score (non-manufacturers) |
12.90 | 17.12 | 25.07 | 12.19 | 5.11 | 5.40 | — | — | — |
Beneish M-Score |
— | (3.75) | (1.79) | (2.39) | 4.40 | — | — | — | — |
P/Operating CF |
(33.80) | (17.25) | (85.31) | (30.82) | (50.03) | (29.85) | — | — | — |
P/B ratio |
2.99 | 1.98 | 3.26 | 2.06 | 2.76 | 1.75 | — | — | — |
Price to Tangible BV |
2.99 | 1.98 | 3.26 | 2.06 | 2.76 | 1.75 | — | — | — |
EV/Sales |
10.49 | 60.84 | 64.18 | 6.98 | 20.99 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(34.03) | (5.75) | (13.02) | (4.08) | (10.52) | 1.13 | — | — | — |
EV/FCF |
(32.93) | (5.66) | (12.76) | (3.92) | (10.04) | 1.14 | — | — | — |
Quick Ratio |
10.87 | 14.68 | 19.38 | 11.51 | 5.49 | 7.39 | 14.26 | 16.62 | 5.41 |
Current Ratio |
11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
Net Debt/EBITDA |
3.88 | 1.95 | 3.70 | 6.11 | 5.28 | 8.49 | 2.27 | 2.48 | 0.93 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.20 | 0.01 | 0.05 | 0.13 | 0.08 | 0.10 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.63 | 0.90 | 1.02 | 1.49 | 1.12 | (1.61) | 0.94 | 0.80 | 1.03 |
Capex/Depreciation |
0.44 | 0.20 | 0.31 | (1.22) | (0.74) | (0.25) | (1.75) | (21.90) | (4.83) |
| (10.92%) | (32.67%) | (23.28%) | (18.02%) | (19.91%) | (23.10%) | (163.16%) | 106.19% | 36.68% | |
| (10.18%) | (30.95%) | (21.78%) | (15.25%) | (14.64%) | (16.77%) | (40.06%) | (71.15%) | (20.81%) | |
ROIC |
(25.96%) | (53.38%) | (87.54%) | 0.00% | (57.39%) | 0.00% | (1,916.16%) | 0.00% | 0.00% |
Return on Tangible Assets |
(18.45%) | (42.06%) | (22.08%) | (16.99%) | (23.63%) | (13.57%) | (42.25%) | (37.99%) | (79.69%) |
Average Days of Receivables |
0.00 | 0.16 | 0.28 | 1.51 | 14.41 | 35.07 | — | — | — |
Research and Development Expense of Revenue |
143.89% | 4,209.61% | 553.81% | 175.80% | 208.15% | 203.18% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
28.95% | 561.46% | 121.04% | 46.92% | 71.76% | 77.72% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
21.08% | 496.37% | 79.06% | 22.83% | 29.48% | 18.47% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.19 | 0.30 | 0.25 | 0.46 | 0.21 | 0.54 | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(3.73%) | (12.84%) | (5.59%) | (8.00%) | (5.88%) | (10.93%) | — | — | — |
Free Cash Flow Yield |
(2.40%) | (11.98%) | (5.80%) | (12.58%) | (7.01%) | 15.82% | — | — | — |
Revenue per Share |
2.47 | 0.09 | 0.41 | 1.23 | 0.79 | 0.79 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.80) | (3.03) | (2.00) | (2.10) | (1.58) | 2.24 | (3.15) | (28.89) | (17.59) |
Capex per Share |
(0.03) | (0.05) | (0.04) | (0.08) | (0.07) | (0.02) | (0.11) | (1.79) | (2.53) |
Free Cash Flow per Share |
(0.83) | (3.08) | (2.04) | (2.19) | (1.66) | 2.22 | (3.25) | (30.68) | (20.12) |
Cash per Share |
7.23 | 8.28 | 9.13 | 8.80 | 7.00 | 11.47 | 7.92 | 94.10 | 18.93 |
Shareholders Equity per Share |
11.56 | 12.97 | 10.80 | 8.43 | 8.55 | 8.02 | 8.03 | (51.20) | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.56 | 12.97 | 10.80 | 8.43 | 8.55 | 8.02 | 8.03 | (51.20) | 0.00 |
Free Cash Flow |
(73.47) | (251.44) | (117.59) | (90.62) | (58.42) | 54.97 | (40.67) | (29.33) | (13.98) |
Working Capital |
607.91 | 643.64 | 505.53 | 338.74 | 205.84 | 249.97 | 94.71 | 85.25 | 11.14 |
Capital Expenditures |
(2.37) | (3.86) | (2.37) | (3.44) | (2.64) | (0.49) | (1.35) | (1.71) | (1.76) |
Net Current Asset Value |
580.34 | 624.77 | 504.41 | 331.94 | 171.16 | 188.61 | 89.05 | (54.82) | 13.58 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.01 | 0.55 | 0.10 | 0.07 | 0.09 | 0.03 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
(0.66) | (2.16) | (1.22) | 0.43 | 0.75 | 0.46 | 0.17 | 0.02 | 0.10 |
Cash ROIC |
(4.42%) | (14.49%) | (10.26%) | (12.69%) | (10.66%) | 11.41% | (20.40%) | (71.51%) | (106.26%) |
Accounts Receivable Turnover |
0.00 | 666.67 | 204.24 | 77.52 | 18.75 | 13.11 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.01 | 0.11 | 0.66 | 1.49 | 1.49 | — | — | — |
Average Payables |
16.50 | 11.01 | 5.44 | 3.19 | 1.53 | 0.83 | 1.06 | 1.04 | 1.04 |
Average Assets |
1,116.71 | 886.70 | 518.64 | 384.66 | 339.81 | 205.64 | 104.77 | 48.27 | 57.01 |
Average Common Equity |
1,041.04 | 840.12 | 485.27 | 325.48 | 249.89 | 149.34 | 25.73 | (32.34) | (32.34) |
Columns are period end dates